JAMA Oncology Author Interviews

Interview with Emmanouil Fokas, MD, DPhil, author of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. Hosted by Jack West, MD.

Interview with Abdul Rafeh Naqash, MD, and Caroline A. Nebhan, MD, PhD, authors of Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. Hosted by Jack West, MD.

Interview with Laura J. Esserman, MD, and W. Fraser Symmans, MD, authors of Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial

Interview with Puneeth Iyengar, MD, PhD, author of Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non–Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial

Interview with Carsten Finke, MD, and Frederik Bartels, MD, authors of Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer

Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial

Interview with David R. Raleigh, MD, PhD, and William C. Chen, MD, authors of Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases: A Systematic Review and Meta-analysis

Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Interview with Douglas B. Johnson, MD, author of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

Interview with Luc GT Morris, MD MSc, author of Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase